News Article | May 5, 2017
NEW YORK, NY / ACCESSWIRE / May 5, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-01565, is on behalf of a class consisting of investors who purchased or otherwise acquired Scynexis securities: (1) pursuant and/or traceable to Scynexis' false and misleading Registration Statement and Prospectus, issued in connection with the Company's initial public offering on or about May 2, 2014 (the "IPO" or the "Offering"); and/or (2) on the open market between May 2, 2014 and March 2, 2017, both dates inclusive (the "Class Period"), seeking to recover damages caused by defendants' violations of the Securities Act of 1933 (the "Securities Act") and the Securities Exchange Act of 1934 (the "Exchange Act"). If you are a shareholder who purchased Scynexis securities between May 2, 2014 and March 2, 2017, both dates inclusive, you have until May 8, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. [Click here to join this class action] Scynexis, Inc. is a pharmaceutical company that develops and distributes intravenous drugs for the treatment of serious and life-threatening invasive fungal infections in humans. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Scynexis's lead product, SCY-078, entailed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug's approval prospectus and/or commercial viability; and (iii) as a result of the foregoing, Scynexis's public statements were materially false and misleading at all relevant times. On March 2, 2017, post-market, Scynexis issued a press release, attached as Exhibit 99.1 on Form 8-K, entitled, "Scynexis delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA's request," announcing the FDA's clinical hold on clinical trials for the intravenous formulation of the Company's lead product candidate, SCY-078. The Company stated that "[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study." On this news, Scynexis's share price fell $0.57, or 17.43%, to close at $2.70 on March 3, 2017. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Fischer G.,Max Planck Research Unit for Enzymology and Protein Folding |
Gallay P.,Scripps Research Institute |
Hopkins S.,Scynexis, Inc.
Current Opinion in Investigational Drugs | Year: 2010
Cyclophilins (Cyps) constitute one of the three families of peptidyl prolyl isomerase enzymes. CypA is the prototypical member of the Cyp family and is the predominant Cyp expressed in human cells. Recent studies indicate that CypA has an essential role in supporting HCV-specific RNA replication and protein expression. CypA interacts with several virally expressed proteins, including the non-structural (NS) proteins NS2, NS5A and NS5B, and may regulate diverse activities ranging from polypeptide processing to viral assembly. The introduction of non-immunosuppressive Cyp inhibitors into clinical trials confirms that Cyp inhibition is a valid strategy for developing novel therapeutics for the treatment of chronic HCV infection. This review describes the cyclophilin protein family and the potential roles played by cyclophilins in supporting HCV RNA replication and protein expression, as well as the initial clinical results obtained with a novel series of non-immunosuppressive cyclophilin inhibitors that established the clinical proof of concept for this emerging class of therapeutic agents. © Thomson Reuters (Scientific) Ltd.
Jacobs R.T.,Scynexis, Inc. |
Nare B.,Scynexis, Inc. |
Phillips M.A.,University of Texas Southwestern Medical Center
Current Topics in Medicinal Chemistry | Year: 2011
African sleeping sickness is endemic in sub-Saharan Africa where the WHO estimates that 60 million people are at risk for the disease. Human African trypanosomiasis (HAT) is 100% fatal if untreated and the current drug therapies have significant limitations due to toxicity and difficult treatment regimes. No new chemical agents have been approved since eflornithine in 1990. The pentamidine analog DB289, which was in late stage clinical trials for the treatment of early stage HAT recently failed due to toxicity issues. A new protocol for the treatment of late-stage T. brucei gambiense that uses combination nifurtomox/eflornithine (NECT) was recently shown to have better safety and efficacy than eflornithine alone, while being easier to administer. This breakthrough represents the only new therapy for HAT since the approval of eflornithine. A number of research programs are on going to exploit the unusual biochemical pathways in the parasite to identify new targets for target based drug discovery programs. HTS efforts are also underway to discover new chemical entities through whole organism screening approaches. A number of inhibitors with anti-trypanosomal activity have been identified by both approaches, but none of the programs are yet at the stage of identifying a preclinical candidate. This dire situation underscores the need for continued effort to identify new chemical agents for the treatment of HAT. © 2011 Bentham Science Publishers Ltd.
Peel M.,Scynexis, Inc. |
Scribner A.,Scynexis, Inc.
Biochimica et Biophysica Acta - General Subjects | Year: 2015
Background Since its isolation in 1970, and discovery of its potent inhibitory activity on T-cell proliferation, cyclosporin A (CsA) has been shown to play a significant role in diverse fields of biology. Furthermore, chemical modification of CsA has led to analogs with distinct biological activities associated with its protein receptor family, cyclophilins. Scope of review This review systematically collates the synthetic chemistry performed at each of the eleven amino acids, and provides examples of the utility of such transformations. The various modifications of CsA are traced from early, modest chemistry performed at the unique Bmt residue, through the remarkable use of a polyanion enolate that can be stereoselectively manipulated, and onto application of more recently developed olefin metathesis chemistry to prepare new CsA derivatives with unexpected biological activity. Major conclusions The myriad biological activities of CsA and its synthetic derivatives have inspired the development of new approaches to modify the CsA ring. In turn, these new CsA derivatives have served as tools in the discovery of new roles for cyclophilins. General significance This review provides information on the types of cyclosporin derivatives that are available to the many biologists working in this field, and should be of value to the medicinal chemist trying to discover drugs based on CsA. This article is part of a Special Issue entitled Proline-directed foldases: Cell signaling catalysts and drug targets. © 2015 Elsevier B.V. All rights reserved.
Peel M.,Scynexis, Inc. |
Scribner A.,Scynexis, Inc.
Bioorganic and Medicinal Chemistry Letters | Year: 2013
Cyclophilins (Cyps) are ubiquitous proteins that effect the cis-trans isomerization of Pro amide bonds, and are thus crucial to protein folding. CypA is the most prevalent of the ∼19 human Cyps, and plays a crucial role in viral infectivity, most notably for HIV-1 and HCV. Cyclophilins have been shown to play key roles in effective replication of a number of viruses from different families. A drug template for CypA inhibition is cyclosporine A (CsA), a cyclic undecapeptide that simultaneously binds to both CypA and the Ca 2+-dependent phosphatase calcineurin (CN), and can attenuate immune responses. Synthetic modifications of the CsA scaffold allows for selective binding to CypA and CN separately, thus providing access to novel, non-immunosuppressive antiviral agents. © 2013 Elsevier Ltd. All rights reserved.
Heasley B.,Scynexis, Inc.
European Journal of Organic Chemistry | Year: 2011
Limonoid natural products are a large family of oxygenated terpenoid compounds that are best known as secondary metabolites found in citrus fruit. The diverse array of significant bioactivities associated with limonoids has stimulated targeted synthetic investigations that are often confounded by complex three-dimensional landscapes and dense functionalization within a compact molecular framework. This Microreview aims to delineate the various structural subcategories of the limonoid aglycon class as well as provide an overview of synthetic efforts invested toward the laboratory preparation of these fascinating molecules. Limonoid natural products are a large family of oxygenated terpenoid compounds that are best known as secondary metabolites found in citrus fruit. This Microreview provides a synopsis of the organic chemistry that has been applied over the last three decades to the synthesis of limonoid tetranortriterpenoids. © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Jacobs R.T.,Scynexis, Inc. |
Plattner J.J.,Anacor Pharmaceuticals Inc. |
Keenan M.,Murdoch University
Current Opinion in Infectious Diseases | Year: 2011
PURPOSE OF REVIEW: Boron-based drugs represent a new class of molecules that have been found to exhibit attractive properties and activities against a number of protozoans causative of neglected tropical diseases. RECENT FINDINGS: This review highlights recent advances in discovery of potential treatments for human African trypanosomiasis, malaria and Chagas disease from a class of boron-containing drugs, the benzoxaboroles. SUMMARY: Research at several biotechnology companies, sponsored by product development partners (PDPs), has been successful in identifying a novel class of boron-based drugs, the benzoxaboroles, as potential treatments for neglected tropical diseases. This work was based, in part, on the earlier observation of antifungal, antibacterial and anti-inflammatory activities of the benzoxaboroles. The unique properties of boron, namely its ability to reversibly interact with biochemical targets through an empty p-orbital, are important to the success of these new drug candidates. Physicochemical and pharmacokinetic properties of the boron-based compounds are consistent with features required for oral absorption, metabolic stability and low toxicity - all important for progression of this class to clinical trials. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Scynexis, Inc. | Date: 2012-01-12
Methods of predicting the response in a patient infected with hepatitis C virus (HCV) to a treatment regime involving the use of a cyclophilin-binding compound are described which provide for improvements in treatments, pharmaceutical compositions, dosing regimen, assays, kits, and other aspects of the art.
Scynexis, Inc. | Date: 2014-11-14
News Article | December 6, 2016
— The report titled “Global Antifungal Market With Focus on Invasive Fungal Infections: 2016-2020” provides an in-depth analysis of the global antifungal market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Azole, Echinocandins and Polyene. Complete report on Antifungal market spread across 63 pages providing 3 company profiles and 5 tables and 27 figures is now available at http://www.marketreportsonline.com/502627.html. The report analysis the invasive fungal infection market extensively with the market size, in terms of value along with the market segments and the major products in the market. This section also provides information about the regional market share of the global invasive fungal infection market. The report provides detailed regional analysis of the United States, Europe and Latin America. The regional analysis of the antifungal market includes market size by value along with the geographic overview of the market in the concerned region. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the antifungal industry. Growth of the overall global antifungal market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global antifungal market is stiff and dominated by the big players like Pfizer. Further, key players of the market, Merck and Scynexis are also profiled with their financial information and respective business strategies. Company Coverage of Antifungal Market: Pfizer, Inc., Merck Co., Inc. & Scynexis, Inc. The global antifungal market witnessed an upsurge at a significant CAGR during 2012-2015 and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market is spread across the globe with the United States and Europe dominating the market, while Asia-Pacific and Latin America market are the fastest growing markets. The antifungal market can be segmented on the basis of types of drugs into Polyene, Azole and Echinocandins. The Azole class of antifungals dominates the market followed, by Echinocandins and Polyene. Azoles are broadly categorized as Voricanazole, Imidazole, Triazole and Thiazoles. Of which, Voricanazole govern the market. Echinocandins antifungal class is subjugated by Caspofungin, while other antifungals include Micafungin, and Anidulafungin. The Polyene antifungal agents include Amphotericin B, Nystatin, and Natamycin. Though, Amphotericin B is the only widely used agent in the market. The fungal infections do not usually result in severe ailment, but in people with weak immune system, minor fungal infections can move in the bloodstreams and conquer critical organs leading to the damage, called as invasive fungal infection. The global market for the invasive fungal infection increased significantly during 2010-2015 and is expected to upsurge further. Purchase a copy of this “Global Antifungal Market With Focus on Invasive Fungal Infections: 2016-2020” research report at USD 850 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=502627. The major growth drivers for the global antifungal market are: the rise in the incidences of fungal infection, aging population and unhygienic conditions all over the world. Despite the market is governed by various growth drivers, there are certain challenges faced by the market such as: antifungal resistance, traditional treatments for fungal infection, side-effects of antifungal medication and antifungal development failures Some of the recent trends in the market include technological advancement, growth in resistant strains and generic competition. Major Points from List of Tables & Figures (http://www.marketreportsonline.com/502627-toc.html) provided in global Antifungal Market: Table 1: Azole Class of Antifungal Drug Types Table 2: Echinocandins Class of Antifungal Drug Types Table 3: Polyene Class of Antifungal Drug Types Table 4: Global Antifungal Market Major Players by Drug Type Table 5: Global Antifungal Market Emerging Players Figure 1: Global Antifungal Market by Value; 2012-2015 (US$ Billion) Figure 2: Global Antifungal Market by Value; 2016E-2020E (US$ Billion) Figure 3: Global Antifungal Market by Drug Segments; 2015 (%) Figure 4: Global Azole Class of Antifungal Market by Value; 2012-2015 (US$ Billion) Figure 5: Global Azole Class of Antifungal Market by Value; 2016E-2020E (US$ Billion) Figure 6: Global Echinocandins Class of Antifungal Market by Value; 2012-2015 (US$ Billion) Figure 7: Global Echinocandins Class of Antifungal Market by Value; 2016E-2020E (US$ Billion) Figure 8: Global Polyene Class of Antifungal Market by Value; 2012-2015 (US$ Billion) Figure 9: Global Polyene Class of Antifungal Market by Value; 2016E-2020E (US$ Billion) Figure 10: Global Antifungal Market by Region; 2015 (%) Figure 11: The U.S. Antifungal Market by Value; 2015-2020E (US$ Billion) Figure 12: Europe Antifungal Market by Value; 2015-2020E (US$ Billion) Global Antifungal Therapeutics Market: Trends and Opportunities: Antifungal agents are drugs used for the treatment of fungal infections that can infect almost any part of the body including skin, nails, respiratory tract, urogenital tract and alimentary tract. Treatment of fungal infections currently available in the market can be broadly classified into four major classes of antifungal drugs – Polyenes, Azoles, Allylamines and Echinocandins. Global antifungal market is dominated by systemic antifungal infection. Complete report available at http://www.marketreportsonline.com/351337.html. For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=502627